Drug Profile
Metformin controlled release - Bristol-Myers Squibb/Merck
Alternative Names: Glucophage extended release reduced mass; Glucophage SR; Glucophage XR; Glucophage XR RM; Metformin extended release - Bristol-Myers Squibb; Metformin extended release - Merck; Metformin hydrochloride - Merck; Metformin XR - Bristol-Myers SquibbLatest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Bristol-Myers Squibb; Merck & Co; Zuellig Pharma
- Class Antihyperglycaemics; Biguanides; Eye disorder therapies; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 03 Jan 2023 Merck & Co completes a phase I bioequivalence trial in Healthy volunteers in Germany (PO) (NCT05463094)
- 01 Aug 2022 NCT05463094= Feedback incorporated
- 25 Jul 2022 Merck Healthcare initiates a phase I Bioequivalence trial in Healthy volunteers in Germany (PO) (NCT05463094)